Table 2 The predictive role of radiosensitivity and immune gene signatures for clinical outcome of patients
Study | Cancer type | Sample Size(n) | Outcome |
|---|---|---|---|
Cui et al. (2018) [91] | Breast cancer | 1439 | Patients treated with radiotherapy had significantly better DSS in the immune-effective group (HR 0.46; P = 0.0076). Both radiosensitivity and immune signatures could predict the benefit from radiotherapy (Pinteraction=0.007 and 0.005). |
Jang et al. (2018) [92] | Lower grade glioma | 511 | Patients classified as the PD-L1-high-radioresistant group showed a detrimental effect on OS rate and may benefit most from radiotherapy combined with immunotherapy (HR: 1.96; CI: 1.01–3.80; p = 0.047). |
Jang et al. (2020) [93] | Glioblastoma | 399 | PD-L1-high-radioresistant group could potentially benefit from radiotherapy combined with immunotherapy and angiogenesis inhibition (HR, 1.70, 95%CI, 1.03–2.81; p = 0.037). |
Dai et al. (2021) [94] | Head and neck squamous cell carcinoma | 288 | The survival rate and B cell count of the radioresistant and PD-L1-high group were lower than those of the other groups (p < 0.05). |
Sun et al. (2021) [97] | Head and neck squamous cell carcinoma | 392 | Only patients in the radiosensitive-immune group had better OS after receiving radiotherapy (HR 0.194, 95%CI 0.788–0.480; p < 0.001). |